Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature
- PMID: 21715538
- DOI: 10.1210/jc.2011-1166
Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course--case report and review of the literature
Abstract
Context: Although pituitary adenomas are common, pituitary carcinoma is a very rare condition.
Objective: We report on a 48-yr-old male presenting with pituitary carcinoma with malignant growth from the beginning and a fulminant clinical course and give an overview of the previously reported cases, paying special attention to clinical and histological parameters that may predict the clinical course.
Methods: We performed a MEDLINE search for previously published cases of pituitary carcinoma and analyzed the clinical, laboratory, and radiological findings.
Results: Ki-67 index and the number of metastatic diseases found on postmortem examination were significantly increased in patients with no treatment response compared to those with some treatment response (P = 0.03 and P = 0.02, respectively). In contrast, time to occurrence of metastatic disease and time to death were significantly shortened in patients with no treatment response (P = 0.01 and P = 0.02, respectively). No differences were found between the two groups for gender distribution, tumor size, mitotic activity assessed as the number of mitotic figures per 10 high-power fields, and number of locations of metastatic disease.
Conclusion: Frequently relapsing, invasive adenoma should raise a suspicion of a malignant disease. Clinically only the presence of metastases is a criterion of malignancy. A high Ki-67 index in the pituitary carcinoma and early manifestation of metastatic disease appear to predict rapid disease progression.
Similar articles
-
Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review.Pituitary. 2018 Jun;21(3):290-301. doi: 10.1007/s11102-018-0872-8. Pituitary. 2018. PMID: 29404894 Review.
-
ACTH-secreting Crooke cell carcinoma of the pituitary.Eur J Clin Invest. 2013 Jan;43(1):20-6. doi: 10.1111/eci.12010. Epub 2012 Nov 7. Eur J Clin Invest. 2013. PMID: 23134557
-
p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1. Neurosurgery. 1996. PMID: 8692397
-
Carcinomas of the pituitary: definition and review of the literature.Gen Diagn Pathol. 1995 Oct;141(2):81-92. Gen Diagn Pathol. 1995. PMID: 8548598 Review.
-
[Metastatic breast carcinoma in the pituitary gland (author's transl)].No To Shinkei. 1978 Jan;30(1):69-73. No To Shinkei. 1978. PMID: 637955 Japanese.
Cited by
-
Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment.J Clin Endocrinol Metab. 2023 Jun 16;108(7):1585-1601. doi: 10.1210/clinem/dgad098. J Clin Endocrinol Metab. 2023. PMID: 36856733 Free PMC article.
-
Cytomorphology of pituitary carcinoma metastatic to liver diagnosed by fine-needle aspiration: A rare case report and review of literature.Cytojournal. 2022 Sep 5;19:51. doi: 10.25259/Cytojournal_6_2021. eCollection 2022. Cytojournal. 2022. PMID: 36128468 Free PMC article.
-
The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas.Int J Mol Sci. 2022 Apr 27;23(9):4861. doi: 10.3390/ijms23094861. Int J Mol Sci. 2022. PMID: 35563252 Free PMC article.
-
A Silent Corticotroph Pituitary Carcinoma: Lessons From an Exceptional Case Report.Front Endocrinol (Lausanne). 2021 Dec 21;12:784889. doi: 10.3389/fendo.2021.784889. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34992581 Free PMC article.
-
Aggressive pituitary tumours and pituitary carcinomas.Nat Rev Endocrinol. 2021 Nov;17(11):671-684. doi: 10.1038/s41574-021-00550-w. Epub 2021 Sep 7. Nat Rev Endocrinol. 2021. PMID: 34493834 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical